+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Precision Cancer Imaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 180 Pages
  • November 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6294634
The precision cancer imaging market size is projected to expand from USD 14.63 billion in 2026 to USD 29.62 billion by 2032, registering a CAGR of 12.47% between 2027 and 2032. This report is Segmented by Component (Hardware, and More), Imaging Modality (Magnetic Resonance Imaging, and More), Cancer Type (Breast Cancer, and More), Application (Screening and Early Detection, and More), Deployment (On-Premises and Cloud-Based), End User (Hospitals and Clinics, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Precision Cancer Imaging Market Trends and Insights

Rising Global Cancer Incidence and Screening Demand

Cancer screening programs are expanding while diagnostic capacity remains uneven across countries. The World Health Assembly recognized medical imaging as essential to diagnosis in May 2025 and called on member states to strengthen imaging capacity and address access gaps. This policy direction supports the precision cancer imaging market because earlier detection creates demand for diagnostic workups, staging, and follow-up imaging. Capacity constraints are likely to favor mobile systems, portable CT, low-field MRI, and cloud-connected workflows in places where fixed installations remain difficult to fund. National health agencies in Southeast and South Asia are gradually widening the setting in which imaging equipment can be procured. Suppliers therefore need different commercial models for mature premium sites and for smaller city hospitals that are newly able to adopt advanced imaging.

Expansion of Precision Oncology and Personalized Treatment

Precision oncology requires imaging at several points in a patient’s care pathway, including staging, treatment selection, response assessment, and surveillance. A 2025 review found that AI-assisted imaging reduced reading time by 21% to 53% and improved lesion characterization by 9% to 20% compared with unassisted interpretation. These gains can make repeated imaging workflows more manageable for radiology teams with limited staff. The precision cancer imaging market benefits when imaging becomes a recurring requirement rather than a one-time diagnostic procedure. In prostate cancer, PSMA-PET can support selection, restaging, and post-treatment evaluation across the patient pathway. Work by the Cardiovascular and Interventional Radiological Society of Europe on imaging biomarkers may also support the use of validated imaging endpoints in clinical studies.

High Capital and Lifecycle Cost of Advanced Imaging Systems

PET/CT, total-body PET, and high-field MRI installations require substantial equipment, facility, and service investment. Large health systems are responding through multi-year agreements that combine equipment, maintenance, software, and training. GE HealthCare signed a 14-year Care Alliance with UC San Diego Health in October 2025 covering several imaging and nuclear medicine modalities. These agreements can reduce immediate purchasing barriers for integrated health systems. They can also narrow procurement options when hardware, AI software, and service are included under a single supplier relationship. The precision cancer imaging market may therefore see imaging capacity concentrated in larger cancer centers and academic systems that can support high-throughput use.

Other drivers and restraints analyzed in the detailed report include:

  1. Adoption of Molecular Imaging and Targeted Radiopharmaceuticals
  2. Integration of Artificial Intelligence and Quantitative Image Analytics
  3. Shortage of Specialized Imaging and Nuclear Medicine Professionals

Segment Analysis

Hardware held 56.37% of the precision cancer imaging market share in 2026, reflecting the large installed base of PET, CT, MRI, and ultrasound systems. Every clinical imaging workflow still depends on physical scanner infrastructure, even where AI is used for interpretation or care coordination. This gives hardware suppliers recurring revenue opportunities from maintenance, upgrades, replacement cycles, and service contracts. Hospitals also need dependable uptime and trained personnel to use these systems safely. Multi-year enterprise arrangements are becoming a practical way to cover equipment, support, and staff training together. GE HealthCare’s 2025 agreement with UC San Diego Health covered X-ray, CT, PET/CT, PET/MR, SPECT/CT, MRI, and nuclear medicine services. Such arrangements support established equipment suppliers, but they can make access more difficult for independent software providers.

Software is forecast to record a 12.81% CAGR through 2032 within the precision cancer imaging market. Growth is supported by AI tools that assist image review and enterprise platforms that connect images, reports, and clinical decisions. The FDA clearance of InferRead Lung CT.AI shows that specific software functions with defined performance claims can move through established regulatory routes. Software can be purchased with a new scanner or deployed across a mixed fleet of equipment. That flexibility broadens its use in hospital networks seeking common analytics and workflow tools. Its value still depends on validation, interoperability, and clinician acceptance. The precision cancer imaging market is therefore likely to retain hardware as its base while software becomes more closely embedded in care delivery.

PET held 33.47% of the precision cancer imaging market share in 2026. Its leading position reflects the use of molecular imaging in prostate cancer staging, biochemical recurrence detection, and theranostic selection. PSMA-PET agents are increasingly tied to radioligand therapy decisions, which can create repeat imaging needs during a patient’s care. Gozellix received FDA approval in March 2025 as a PSMA-PET agent with an extended 6-hour shelf life. This formulation can support delivery to more PET sites. PET also has a central role where imaging is used to determine whether a patient is suitable for targeted treatment. The modality’s role is consequently moving beyond a staging support function.

MRI is forecast to expand at a 13.42% CAGR through 2032, the fastest rate among the listed modalities. It benefits from wider use in dense-breast imaging and from prostate imaging before biopsy. A 2025 review reported evidence that AI-supported imaging can reduce reading time while improving lesion characterization. MRI offers detailed soft-tissue visualization without ionizing radiation, which supports its use in repeat assessment pathways. CT continues to serve high-volume staging, lung screening, and treatment planning needs. Ultrasound and contrast-enhanced ultrasound remain accessible options in breast and liver cancer evaluation. Together, these modalities show how the precision cancer imaging market can meet different clinical and cost needs.

Complete Report Scope:

  • By Component
    • Hardware
    • Software
    • Services
  • By Imaging Modality
    • Magnetic Resonance Imaging (MRI)
    • Computed Tomography (CT)
    • Positron Emission Tomography (PET)
    • Ultrasound and Contrast-Enhanced Ultrasound
    • Others
  • By Cancer Type
    • Breast Cancer
    • Lung Cancer
    • Prostate Cancer
    • Colorectal Cancer
    • Others
  • By Application
    • Screening and Early Detection
    • Diagnosis and Staging
    • Treatment Planning
    • Treatment Monitoring and Response Assessment
    • Others
  • By Deployment
    • On-Premises
    • Cloud-Based
  • By End User
    • Hospitals and Clinics
    • Cancer Care Centers
    • Diagnostic Imaging Centers
    • Others
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held 39.48% of the precision cancer imaging market revenue share in 2026. The region has a dense base of academic cancer centers, community hospitals, and freestanding imaging facilities. It also has a strong foundation for PET, CT, MRI, and nuclear medicine services. Regulatory and payment decisions influence which imaging agents and technologies reach patients. FDA approvals in 2025 for Gozellix and the earlier use of Pluvicto supported the use of PSMA-directed imaging and therapy in prostate cancer pathways. Telix also reported FDA approval of an Illuccix label expansion for pre-taxane patient selection in June 2025. Long-term equipment alliances are reinforcing the role of large health systems in advanced imaging adoption. GE HealthCare’s 14-year UC San Diego Health agreement is one example of this model. The region’s structural advantage comes from its installed base, specialist workforce, and ability to translate regulatory approvals into clinical use.

Asia-Pacific is forecast to expand at a 15.88% CAGR through 2032. Cancer burden, hospital modernization, and the need for more imaging access are supporting growth across the region. The available MRI capacity remains limited in many Southeast Asian health systems. A 2025 assessment identified shortages of MRI equipment and trained professionals, along with long waiting times, as major barriers to access. This capacity gap supports demand for practical equipment choices and for tools that improve workflow efficiency. The World Health Assembly’s 2025 resolution on medical imaging offers policy support for national capacity-building efforts. Japan and South Korea are earlier adopters of advanced imaging and AI-enabled workflows, while other parts of the region require broader infrastructure development. Suppliers that can pair equipment with local support, training, and scalable service models are better positioned to address this varied demand.

Europe has established nuclear medicine services and remains important for molecular imaging, theranostics, and quantitative imaging work. European facilities operate within radiation safety and clinical quality frameworks that influence facility design, staff qualifications, and tracer use. The EU Basic Safety Standards Directive is a relevant compliance factor for nuclear medicine services. The United Kingdom and Italy are advancing lung cancer CT screening approaches, while AI assessment tools are being considered as a way to manage reading workloads. The EU AI Act also affects medical AI tools classified as high-risk systems, encouraging suppliers to build stronger documentation, monitoring, and explainability practices. In the Middle East and Africa, imaging adoption is at an earlier stage outside larger health systems, while access is constrained by financing and workforce limits. South American use is concentrated in major urban cancer centers, with nuclear medicine capability influencing where advanced PET services can operate. Across these mixed regions, the International Atomic Energy Agency’s radiation protection frameworks shape planning for new nuclear medicine facilities. These requirements make service capability, training, and regulatory readiness as important as equipment delivery for the precision cancer imaging market.



List of Companies Covered in this Report:

  1. Aidoc Medical Ltd
  2. Bayer
  3. Bracco
  4. Brain Lab
  5. Canon
  6. Curium Pharma
  7. Eckert & Ziegler SE
  8. FUJIFILM
  9. GE Healthcare
  10. Hologic
  11. Koninklijke Philips
  12. Lantheus
  13. Lunit
  14. Median Technologies
  15. Mirada Medical Limited
  16. Novartis
  17. Paige AI Inc.
  18. PathAI Inc.
  19. Quibim S.L.
  20. Qure.ai Technologies Private Limited
  21. Shimadzu
  22. Siemens Healthineers
  23. Telix Pharmaceuticals Limited
  24. Tempus AI Inc.
  25. United Imaging Healthcare

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Global Cancer Incidence and Screening Demand
4.2.2 Expansion of Precision Oncology and Personalized Treatment
4.2.3 Adoption of Molecular Imaging and Targeted Radiopharmaceuticals
4.2.4 Integration of Artificial Intelligence and Quantitative Image Analytics
4.2.5 Localized Radiopharmaceutical Production Improves Tracer Availability
4.2.6 Multimodal Imaging Becomes a Treatment-Planning Data Layer
4.3 Market Restraints
4.3.1 High Capital and Lifecycle Cost of Advanced Imaging Systems
4.3.2 Shortage of Specialized Imaging and Nuclear-Medicine Professionals
4.3.3 Reimbursement and Radiation-Exposure Constraints
4.3.4 Interoperability and Clinical-Validation Friction for Radiomics
4.4 Value and Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Buyers
4.7.3 Bargaining Power of Suppliers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Component
5.1.1 Hardware
5.1.2 Software
5.1.3 Services
5.2 By Imaging Modality
5.2.1 Magnetic Resonance Imaging (MRI)
5.2.2 Computed Tomography (CT)
5.2.3 Positron Emission Tomography (PET)
5.2.4 Ultrasound and Contrast-Enhanced Ultrasound
5.2.5 Others
5.3 By Cancer Type
5.3.1 Breast Cancer
5.3.2 Lung Cancer
5.3.3 Prostate Cancer
5.3.4 Colorectal Cancer
5.3.5 Others
5.4 By Application
5.4.1 Screening and Early Detection
5.4.2 Diagnosis and Staging
5.4.3 Treatment Planning
5.4.4 Treatment Monitoring and Response Assessment
5.4.5 Others
5.5 By Deployment
5.5.1 On-Premises
5.5.2 Cloud-Based
5.6 By End User
5.6.1 Hospitals and Clinics
5.6.2 Cancer Care Centers
5.6.3 Diagnostic Imaging Centers
5.6.4 Others
5.7 By Geography
5.7.1 North America
5.7.1.1 United States
5.7.1.2 Canada
5.7.1.3 Mexico
5.7.2 Europe
5.7.2.1 Germany
5.7.2.2 United Kingdom
5.7.2.3 France
5.7.2.4 Italy
5.7.2.5 Spain
5.7.2.6 Rest of Europe
5.7.3 Asia-Pacific
5.7.3.1 China
5.7.3.2 India
5.7.3.3 Japan
5.7.3.4 Australia
5.7.3.5 South Korea
5.7.3.6 Rest of Asia-Pacific
5.7.4 Middle East and Africa
5.7.4.1 GCC
5.7.4.2 South Africa
5.7.4.3 Rest of Middle East and Africa
5.7.5 South America
5.7.5.1 Brazil
5.7.5.2 Argentina
5.7.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
6.3.1 Aidoc Medical Ltd
6.3.2 Bayer AG
6.3.3 Bracco Imaging SpA
6.3.4 Brainlab AG
6.3.5 Canon Medical Systems Corporation
6.3.6 Curium Pharma
6.3.7 Eckert & Ziegler SE
6.3.8 FUJIFILM Holdings Corporation
6.3.9 GE HealthCare
6.3.10 Hologic Inc.
6.3.11 Koninklijke Philips NV
6.3.12 Lantheus Holdings Inc.
6.3.13 Lunit Inc.
6.3.14 Median Technologies
6.3.15 Mirada Medical Limited
6.3.16 Novartis AG
6.3.17 Paige AI Inc.
6.3.18 PathAI Inc.
6.3.19 Quibim S.L.
6.3.20 Qure.ai Technologies Private Limited
6.3.21 Shimadzu Corporation
6.3.22 Siemens Healthineers AG
6.3.23 Telix Pharmaceuticals Limited
6.3.24 Tempus AI Inc.
6.3.25 United Imaging Healthcare Co. Ltd
7 Market Opportunities and Future Outlook
7.1 White-Space and Unmet-Need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Aidoc Medical Ltd
  • Bayer AG
  • Bracco Imaging SpA
  • Brainlab AG
  • Canon Medical Systems Corporation
  • Curium Pharma
  • Eckert & Ziegler SE
  • FUJIFILM Holdings Corporation
  • GE HealthCare
  • Hologic Inc.
  • Koninklijke Philips NV
  • Lantheus Holdings Inc.
  • Lunit Inc.
  • Median Technologies
  • Mirada Medical Limited
  • Novartis AG
  • Paige AI Inc.
  • PathAI Inc.
  • Quibim S.L.
  • Qure.ai Technologies Private Limited
  • Shimadzu Corporation
  • Siemens Healthineers AG
  • Telix Pharmaceuticals Limited
  • Tempus AI Inc.
  • United Imaging Healthcare Co. Ltd